Pfizer Inc
Close on Nov 2, 2026Market cap $174.81BP/E 40.4Yield 5.61%
Pfizer Historical / Mature / Divested Brands [legacy by Quarter
Historical / Mature / Divested Brands [legacy disclosures] — Vyndaqel/Hospital/Upjohn history ($M) ($M)
Pfizer Historical / Mature / Divested Brands [legacy: $1,916M in Q3 2020, down 18.5% from a year earlier. No newer figure appears in the documents we track.
Where the Q3 2020 figure comes from
Source: Form 10-Q (filed 2020-11-05) ↗
Parent series shows historical Upjohn segment revenue prior to the November 2020 Viatris spin-off; child rows preserve brand histories.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Historical / Mature / Divested Brands [legacy disclosures] — Vyndaqel/Hospital/Upjohn history ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q3 2020 | Sep 27, 2020 | 1,916 | -18.5% | Form 10-Q (filed 2020-11-05) ↗ |
| Q2 2020 | Jun 28, 2020 | 2,006 | -32.5% | Form 10-Q (filed 2020-08-06) ↗ |
| Q1 2020 | Mar 29, 2020 | 2,022 | -37.1% | Form 10-Q (filed 2020-05-07) ↗ |
| Q4 2019 | Dec 31, 2019 | 1,698 | -46.6% | Form 10-K (filed 2020-02-27) ↗ |
| Q3 2019 | Sep 29, 2019 | 2,351 | -22.6% | Form 10-Q (filed 2020-11-05) ↗ |
| Q2 2019 | Jun 30, 2019 | 2,970 | -5.6% | Form 10-Q (filed 2020-08-06) ↗ |
| Q1 2019 | Mar 31, 2019 | 3,214 | +3.0% | Form 10-Q (filed 2020-05-07) ↗ |
| Q4 2018 | Dec 31, 2018 | 3,182 | – | Form 10-K (filed 2020-02-27) ↗ |
| Q3 2018 | Sep 30, 2018 | 3,036 | – | Form 10-Q (filed 2019-11-07) ↗ |
| Q2 2018 | Jul 1, 2018 | 3,147 | – | Form 10-Q (filed 2019-08-08) ↗ |
| Q1 2018 | Apr 1, 2018 | 3,120 | – | Form 10-Q (filed 2019-05-09) ↗ |
Breakdown
What makes up historical / Mature / Divested Brands [legacy
- BeneFIX (coagulation factor IX) [legacy through FY24] — Worldwide revenues ($M)87 · Q4 2024
- Premarin Family (conjugated estrogens) [legacy through FY24] — Worldwide revenues ($M)97 · Q4 2024
- Oxbryta (voxelotor — voluntarily withdrawn Sept 2024) [legacy through FY24] ($M)8 · Q4 2024
- Aromasin (exemestane) [legacy through FY25] ($M)117 · Q4 2025
- All Other Hospital [legacy through FY25] ($M)1,059 · Q4 2025
- Medrol (methylprednisolone) [legacy through FY23] — Worldwide revenues ($M)76 · Q4 2023
- Retacrit (epoetin alfa biosimilar) [legacy through FY23] — Worldwide revenues ($M)79 · Q4 2023
- Ruxience (rituximab biosimilar) [legacy through FY23] — Worldwide revenues ($M)88 · Q4 2023
- Zirabev (bevacizumab biosimilar) [legacy through FY23] — Worldwide revenues ($M)88 · Q4 2023
- Trazimera (trastuzumab biosimilar) [legacy through FY23] — Worldwide revenues ($M)23 · Q4 2023
- Sutent (sunitinib) [legacy through FY23] ($M)44 · Q4 2023
- Xalkori (crizotinib) [legacy through FY23] ($M)91 · Q4 2023
- Besponsa (inotuzumab ozogamicin) [legacy through FY23] ($M)65 · Q4 2023
- Bavencio alliance revenue [legacy through FY23] ($M)4 · Q4 2023
- Chantix / Champix (varenicline) [legacy through FY22] ($M)0 · Q4 2022
- Lyrica (pregabalin — Upjohn spin-off to Viatris Nov 2020) [legacy] ($M)352 · Q3 2020
- Lipitor (atorvastatin — Upjohn spin-off Nov 2020) [legacy] ($M)356 · Q3 2020
- Norvasc (amlodipine — Upjohn spin-off Nov 2020) [legacy] ($M)183 · Q3 2020
- Celebrex (celecoxib — Upjohn spin-off Nov 2020) [legacy] ($M)133 · Q3 2020
- Viagra (sildenafil — Upjohn spin-off Nov 2020) [legacy] ($M)121 · Q3 2020
Cite this data
StockData. (2026). Pfizer Historical / Mature / Divested Brands [legacy ($M), quarterly Q1 2018–Q3 2020 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/legacy-loe-brands
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.